Oncology & Cancer

BRCAPRO model underestimates BRCA1/2 mutation risk

(HealthDay)—Use of the BRCAPRO model for assessment of the likelihood of having a germline BRCA1/BRCA2 mutation, based on age, ethnicity, and family history, may underestimate the risk of mutations, according to a study ...

Oncology & Cancer

Using cancer's fingerprint, researchers clinch a diagnosis

Rochester scientists are using a gene test to diagnose a difficult-to-detect form of bone marrow cancer – an example of how academic medical centers are applying new technology in ways that play to their strengths to achieve ...

Oncology & Cancer

COXEN model picks the best drug for ovarian cancer

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug ...

page 33 from 40